Orsted (OTC:DNNGY) Stock, Quote.Headers.trade-ideas

Danish company Orsted was named Dong Energy until the sale of all its oil and gas fields to Ineos in 2017, soon after the May 2016 initial public offering. Orsted is now focused on renewable assets, especially offshore wind farms. It operated 8.9 gigawatts of offshore wind farms at the end of 2023. The United Kingdom is the biggest country of operation, ahead of Germany and Denmark. The group intends to develop its footprint outside Europe with projects in Taiwan and in the US Orsted also operates 4.8 GW of onshore wind and solar assets concentrated in the United States. The company is also involved in more traditional utilities business like conventional power plants and gas supply, but these activities are noncore.

Modern,Battery,Energy,Storage,System,With,Wind,Turbines,And,Solar

Equities

Large Cap

News

Contracts

Trading Ideas

DNNGY

TSLA

Orsted invests in battery energy storage system to stabilize UK energy supply and reduce price volatility. Tesla&#39;s system will be installed at Hornsea 3 Wind Farm.

Orsted Invests In Tesla-Powered Battery Storage In UK: Details

Penny Stocks

Markets

General

European Aeronautic Defence And Space Unsponsored

EADSY

EJTTF

RLLCF

Airbus SE (OTC: EADSY), easyJet plc (OTC: EJTTF), and Rolls Royce Holdings Plc (OTC: RLLCF) have formed a conso

Carbon-Free Skies: Airbus, easyJet, And Rolls Royce Team Up For UK&#39;s Hydrogen Aviation Revolution

FSLR

RDS-B

SEDG

SPWR

VSLR

The State of Oil Is Falling in Love With Solar Energy

Orsted AS

<p>Melius Research  analyst Karen Short   initiates coverage on Grocery Outlet Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) with a Hold rating and announces Price Target of $17.</p>


Price Target

Initiation

Analyst Ratings

Melius Research Initiates Coverage On Grocery Outlet Holding with Hold Rating, Announces Price Target of $17

<p>HC Wainwright &amp; Co.  analyst Emily Bodnar   reiterates Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) with a Neutral and maintains $6 price target.</p>


Reiteration

VTYX

HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target

WIIM

ORGS

Orgenesis shares are trading lower after the company announced a 1-for-10 reverse stock split.

<p>HC Wainwright &amp; Co.  analyst Emily Bodnar   reiterates Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) with a Buy and maintains $6 price target.</p>


CNTX

HC Wainwright & Co. Reiterates Buy on Context Therapeutics, Maintains $6 Price Target

<p>Baird  analyst Brian Skorney   maintains Biohaven (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) with a Outperform and raises the price target from $58 to $60.</p>


BHVN

Baird Maintains Outperform on Biohaven, Raises Price Target to $60

<p>Wall Street kicked off the week on a cautious note, with major indexes trading relatively flat as investors seek more clarity on the economic and political landscape.</p>
<p>A widely followed private sector survey by <strong>S&amp;P Global</strong> revealed that output growth slightly exceeded expectations in September, buoyed by stronger services activity. However, the report also signaled a reawakening of inflationary pressures, raising concerns about <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40965082/feds-historic-dissenter-bowman-says-smaller-interest-rate-cut-was-justified-we-have-no">future monetary policy moves.</a></p>
<p>The latest betting-implied odds from <strong>Polymarket </strong>show Kamala Harris at 51% to win the 2024 U.S. presidential election, surpassing former President Donald Trump, who has seen his consensus slips in recent weeks.</p>
<p>Among major assets, gold continues its upward momentum, setting new all-time highs as investors flock to safe-haven assets amid global uncertainty.</p>
<p>Meanwhile, natural gas prices spiked over 4%, hitting a three-month high early Monday. The rise follows the formation of another storm in the Gulf of Mexico, which threatens to further disrupt supply chains already impacted by Hurricane Francine.</p>
<p>The geopolitical situation in the Middle East remains tense, with Israel targeting new Hezbollah sites in Lebanon and the U.S. sending additional military troops to the region amid rising conflict. </p>
<p>Despite the turmoil, oil prices fell by 2%, suggesting that supply fears may be easing for the moment. </p>
<p>In the cryptocurrency space, <strong>Bitcoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) eased by 0.5%, showing little movement.</p>
<h1 class="wp-block-heading"><strong>Monday&#8217;s Performance In Major U.S. Indices, ETFs</strong></h1>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Major Indices</strong></td>
<td><strong>Price</strong></td>
<td><strong>1-day %chg</strong></td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,816.41</td>
<td>0.1 %</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,707.19</td>
<td>0.1 %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,002.30</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,213.90</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<p><figcaption class="wp-element-caption"><em>Updated at 12:45 p.m. ET</em></figcaption></p></figure></p>
<p>According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1">Benzinga Pro</a> data: </p>
<ul>
<li>The&nbsp;<strong>SPDR S&amp;P 500 ETF Trust</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;was flat at $568.42.</li>
<li>The&nbsp;<strong>SPDR Dow Jones Industrial Average&nbsp;</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;edged 0.1% lower to $420.26.</li>
<li>The tech-heavy <strong>Invesco QQQ Trust Series</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) flattened at $482.36.</li>
<li>The <strong>iShares Russell 2000 ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.5% to $220.36.</li>
<li>The <strong>Consumer Discretionary</strong> <strong>Select Sector SPDR Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 0.6%. The <strong>Health Care</strong> <strong>Select Sector SPDR Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 0.6%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
<ul>
<li><strong>Tesla Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rallied 4%, while <strong>General Motors Co</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) fell 2.7% reacting to the latest export ban proposal from the U.S. administration <a href="https://www.benzinga.com/markets/asia/24/09/40981254/chinese-vehicle-tech-faces-biden-administration-ban-over-national-security-concerns-china-ev-stocks">on Chinese-made vehicles. </a></li>
<li><strong>Intel Corp.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) rose over 3% amid rumors that<strong> Qualcomm Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) is <a href="https://www.benzinga.com/m-a/24/09/40983591/qualcomm-takeover-of-intel-is-logically-unlikely-in-face-of-regulatory-challenges-analyst-says">exploring a potential takeove</a>r. Shares of Qualcomm fell 2%.</li>
<li><strong>Ciena Corp</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) obtained a double upgrade from Sell to Buy by Citigroup. </li>
<li><strong>Viking Therapeutics Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) fell over 6% amid negative weight-loss study data.</li>
</ul>
<p><strong>Read Now:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40965082/feds-historic-dissenter-bowman-says-smaller-interest-rate-cut-was-justified-we-have-no">Fed&#8217;s Historic Dissenter Bowman Says Smaller Interest Rate Cut Was Justified: &#8216;We Have Not Yet Achieved Our Inflation Goal&#8217;</a></strong></li>
</ul>
<p><em>This image was created using artificial intelligence MidJourney.</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Global

ETFs

$BTC

CIEN

SPDR Dow Jones Industrial Average ETF Trust

INTC

QCOM

VKTX

Select Sector SPDR-Consumer Discretionary

US Stocks Stall, Gold Updates Record Highs, Tesla Rallies: What's Driving Markets Monday?

<p>Investors in <strong>BRC Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/brcc#NYSE">BRCC</a>) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct. 18, 2024 $1 Call had some of the highest implied volatility of all equity options today.</p>
<h2>What is Implied Volatility?</h2>
<p>Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.</p>
<h2>What do the Analysts Think?</h2>
<p>Clearly, options traders are pricing in a big move for BRC shares, but what is the fundamental picture for the company? Currently, BRC is a Zacks Rank #4 (Sell) in the Consumer Products - Staples industry that ranks in the Bottom 44% of our Zacks Industry Rank. Over the last 60 days, no analyst increased the earnings estimates for the current quarter, while four have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from breakeven to a loss of 2 cents in that period.</p>
<p>Given the way analysts feel about BRC right now, this huge implied volatility could mean there&#39;s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.</p>
<p><a href="https://www.zacks.com/stock/news/2339965/is-the-options-market-predicting-a-spike-in-brc-brcc-stock?cid=CS-BENZ-FT-tale_of_the_tape|options-2339965">To read this article on Zacks.com click here.</a></p>


Earnings

Options

Small Cap

BRCC

Is the Options Market Predicting a Spike in BRC Stock?

<p>HC Wainwright &amp; Co.  analyst Yi Chen   maintains Bausch &amp; Lomb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) with a Buy and raises the price target from $19 to $22.</p>


BLCO

HC Wainwright & Co. Maintains Buy on Bausch & Lomb, Raises Price Target to $22

<p>Deep-pocketed investors have adopted a bearish approach towards CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVS usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 32 extraordinary options activities for CVS Health. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 37% leaning bullish and 56% bearish. Among these notable options, 19 are puts, totaling $1,013,010, and 13 are calls, amounting to $1,746,486.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $45.0 and $65.0 for CVS Health, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for CVS Health's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across CVS Health's significant trades, within a strike price range of $45.0 to $65.0, over the past month.</p>
<h3>CVS Health Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727111767_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/25/24</td>
<td>$2.16</td>
<td>$1.91</td>
<td>$1.89</td>
<td>$58.00</td>
<td>$739.1K</td>
<td>42</td>
<td>3.8K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.85</td>
<td>$5.75</td>
<td>$5.78</td>
<td>$55.00</td>
<td>$410.3K</td>
<td>3.2K</td>
<td>710</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$1.45</td>
<td>$1.44</td>
<td>$1.45</td>
<td>$57.00</td>
<td>$149.4K</td>
<td>0</td>
<td>2.0K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.45</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$60.00</td>
<td>$107.1K</td>
<td>6.3K</td>
<td>676</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.45</td>
<td>$3.35</td>
<td>$3.45</td>
<td>$60.00</td>
<td>$99.7K</td>
<td>6.3K</td>
<td>2.1K</td>
</tr>
</tbody>
</table>
</p>
<h3>About CVS Health</h3>
<p>CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.</p>
<p>After a thorough review of the options trading surrounding CVS Health, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of CVS Health</h3>
<ul>
<li>Currently trading with a volume of 2,906,387, the CVS's price is up by 0.51%, now at $57.8. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 44 days.</li>
</ul>
<h3>Professional Analyst Ratings for CVS Health</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $64.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $68.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $62.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $62. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest CVS Health options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Spotlight on CVS Health: Analyzing the Surge in Options Activity

<p>Deep-pocketed investors have adopted a bullish approach towards Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CL usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Colgate-Palmolive. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 2 are puts, totaling $61,200, and 6 are calls, amounting to $228,304.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $95.0 and $105.0 for Colgate-Palmolive, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Colgate-Palmolive options trades today is 881.17 with a total volume of 1,167.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Colgate-Palmolive's big money trades within a strike price range of $95.0 to $105.0 over the last 30 days.</p>
<h3>Colgate-Palmolive Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727111761_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$8.5</td>
<td>$8.3</td>
<td>$8.5</td>
<td>$97.50</td>
<td>$55.2K</td>
<td>520</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.95</td>
<td>$0.9</td>
<td>$0.95</td>
<td>$105.00</td>
<td>$48.0K</td>
<td>2.6K</td>
<td style="text-align: right;">530</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$7.5</td>
<td>$7.2</td>
<td>$7.48</td>
<td>$97.50</td>
<td>$37.4K</td>
<td>612</td>
<td style="text-align: right;">92</td>
</tr>
<tr>
<td>CL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.6</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$95.00</td>
<td>$34.2K</td>
<td>250</td>
<td style="text-align: right;">76</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$4.1</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$100.00</td>
<td>$30.8K</td>
<td>195</td>
<td style="text-align: right;">192</td>
</tr>
</tbody>
</table>
</p>
<h3>About Colgate-Palmolive</h3>
<p>Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.</p>
<p>In light of the recent options history for Colgate-Palmolive, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Colgate-Palmolive</h3>
<ul>
<li>Trading volume stands at 1,380,483, with CL's price up by 0.51%, positioned at $103.59.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 32 days.</li>
</ul>
<h3>Expert Opinions on Colgate-Palmolive</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $110.33333333333333.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wells Fargo has revised its rating downward to Underweight, adjusting the price target to $100.<br />
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Colgate-Palmolive, which currently sits at a price target of $122.<br />
&#x2A; An analyst from Deutsche Bank has revised its rating downward to Hold, adjusting the price target to $109. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Colgate-Palmolive, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Unpacking the Latest Options Trading Trends in Colgate-Palmolive

<p>High-rolling investors have positioned themselves bullish on Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in TXN often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 11 options trades for Texas Instruments. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 63% bullish and 27% bearish. Among all the options we identified, there was one put, amounting to $39,510, and 10 calls, totaling $512,951.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $190.0 and $210.0 for Texas Instruments, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Texas Instruments's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Texas Instruments's whale activity within a strike price range from $190.0 to $210.0 in the last 30 days. </p>
<h3>Texas Instruments Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727111756_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TXN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$16.25</td>
<td>$16.2</td>
<td>$16.25</td>
<td>$200.00</td>
<td>$156.0K</td>
<td>3.2K</td>
<td style="text-align: right;">349</td>
</tr>
<tr>
<td>TXN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$15.85</td>
<td>$15.65</td>
<td>$15.85</td>
<td>$200.00</td>
<td>$76.1K</td>
<td>3.2K</td>
<td style="text-align: right;">76</td>
</tr>
<tr>
<td>TXN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$9.1</td>
<td>$8.6</td>
<td>$8.7</td>
<td>$210.00</td>
<td>$42.6K</td>
<td>1.5K</td>
<td style="text-align: right;">49</td>
</tr>
<tr>
<td>TXN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$4.05</td>
<td>$3.95</td>
<td>$3.95</td>
<td>$205.00</td>
<td>$39.5K</td>
<td>13</td>
<td style="text-align: right;">201</td>
</tr>
<tr>
<td>TXN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.65</td>
<td>$6.5</td>
<td>$6.55</td>
<td>$210.00</td>
<td>$39.3K</td>
<td>1.4K</td>
<td style="text-align: right;">106</td>
</tr>
</tbody>
</table>
</p>
<h3>About Texas Instruments</h3>
<p>Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.</p>
<p>Following our analysis of the options activities associated with Texas Instruments, we pivot to a closer look at the company's own performance.</p>
<h3>Texas Instruments's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,143,121, with TXN's price up by 0.23%, positioned at $203.77.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 29 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Texas Instruments, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Unpacking the Latest Options Trading Trends in Texas Instruments

<p><strong>KB Home </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kbh#NYSE">KBH</a>) is slated to report third-quarter fiscal 2024 results (ended Aug. 31) on Sept. 24, after the closing bell.</p>
<p>In the last reported quarter, KB Home&#39;s earnings and revenues beat the Zacks Consensus Estimate by 20.8% and 4.3%, respectively. On a year-over-year basis, earnings increased 11% on 3.4% lower revenues.</p>
<p>The company&#39;s earnings topped analysts&#39; expectations in 31 of the trailing 34 quarters.</p>
<div class="chart_embed">
<h3>KB Home Price and EPS Surprise</h3>
<p><img alt="KB Home Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/9d/1727092560.png" style="height:263px; width:538px" title="" /></p>
<p>KB Home price-eps-surprise | KB Home Quote</p>
</div>
<h2>How Are Estimates Placed for KBH?</h2>
<p>For the quarter to be reported, the Zacks Consensus Estimate for earnings has remained unchanged at $2.04 per share over the past 60 days. The projected figure indicates an increase of 13.3% from the year-ago quarter&#39;s earnings of $1.80 per share.</p>
<p>The consensus estimate for revenues is pegged at $1.73 billion, implying growth of 8.8% from the prior-year quarter.</p>
<h2>What the Zacks Model Unveils for KB Home</h2>
<p>Our proven model predicts an earnings beat for KB Home this time around. This is because a stock needs to have the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen.</p>
<p><strong>Earnings ESP</strong>: KB Home has an Earnings ESP of +0.08%.</p>
<p><strong>Zacks Rank</strong>: KB Home currently has a Zacks Rank #3.</p>
<h2>Factors to Shape KBH&#39;s Q3 Results</h2>
<p><strong>Revenues</strong>: KB Home&#39;s top line in third-quarter fiscal 2024 is likely to have increased, given higher Housing revenues primarily attributable to growth in deliveries and favorable pricing. The company has been benefiting from the strong buyer demand, particularly for built-to-order homes, despite the volatility in mortgage rates.</p>
<p>The company&#39;s focus on personalization and its ability to offer both quick move-in and personalized homes might have helped the company drive growth. KB Home has also been utilizing mortgage buydowns as a key component of its strategy to maintain strong sales amid fluctuating mortgage rates.</p>
<p>Although the company has not provided an explicit forecast for its third-quarter absorption pace, the positive momentum from the fiscal second quarter &mdash; driven by strong demand, shorter build times, and strategic pricing &mdash; suggests that the absorption pace is expected to remain solid in the fiscal third quarter. The company is focusing on balancing pace and pricing to optimize margins while still driving volume.</p>
<p>The company expects housing revenues in the range of $1.65-$1.75 billion compared with the year-ago figure of $1.57 billion. KBH anticipates the average selling price&nbsp;to be $482,000, indicating an increase from $466,300 reported a year ago.</p>
<p>Our model projects housing revenues to grow 9.1% year over year to $1.72 billion in the quarter. We expect ASP to increase 3.3% to $481,500. We expect total deliveries in the quartet to grow 5.6% year over year.</p>
<p><strong>Margins</strong>: Although initiatives like the Returns-Focused Growth Plan and Built-to-Order approach are positives, increasing construction and labor costs are likely to put pressure on the bottom line.</p>
<p>The company anticipates that the housing gross margin for the third quarter of 2024 will decline between 21% and 21.4% (compared with 21.5% in the year-ago quarter). This projection accounts for the concessions provided to homebuyers in the latter half of last year, which were influenced by the challenging market conditions at that time and is expected to close in this quarter.</p>
<p>Selling, general &amp; administrative expenses (SG&amp;A), as a percentage of housing revenues, are likely to be 9.9%-10.3%. We expect SG&amp;A expenses to be 10.2% in the quarter, the same as the year-ago figure.</p>
<p>The company expects adjusted operating margin between 10.8% and 11.4%. Our model predicts the adjusted operating margin to be 10.9% in the quarter, down from 11.4% a year ago.</p>
<p>The company expects an effective tax rate of approximately 24% for the quarter.</p>
<p><strong>Orders &amp; Backlogs</strong>: We anticipate that new orders will increase to 3,357 units, up 8.4% from the previous year. With a limited supply of pre-owned homes available, homebuyers are turning their attention to builders who have increased their construction efforts to meet the rising demand. KB Home, along with other homebuilding companies, has benefited significantly from this trend despite ongoing challenges.</p>
<p>We expect the backlog to be 6,062 units, implying a decline from 7,008 units reported in the prior-year quarter.</p>
<p>Meanwhile, our model predicts Financial Services revenues to be $8.3 million for the fiscal third quarter. We expect Financial Services pretax income to be $12.2 million in the quarter compared with the year-ago quarter&#39;s figure of $9.9 million.</p>
<h2>KB Home&#39;s Price Performance &amp; Valuation</h2>
<p>KBH&#39;s stock has exhibited an upward movement in the past six months.&nbsp;The stock has gained 27.5%, outperforming the Zacks Building Products - Home Builders industry&#39;s rise of 16.4% in the same time frame.</p>
<p>The company has also outperformed its peer companies like <strong>Meritage Homes Corporation</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mth#NYSE">MTH</a>) (up 21.6% in the past six months) and <strong>Taylor Morrison Home Corporation</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tmhc#NYSE">TMHC</a>) (up 16%).</p>
<h2>6-Month Price Performance of KBH Stock</h2>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/2d/78791.jpg?v=1075297864" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>Technical indicators suggest continued strong performance for KBH. Notably, the 50-day SMA continues to read higher than the 200-day SMA, signaling the bullish trend.</p>
<h2>KBH Stock Trades Above 50 and 200-Day Moving Average</h2>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/55/78793.jpg?v=505003855" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>KBH stock is trading at a discount compared with the industry and slightly higher than its median. Despite the company&#39;s shares&#39; outperformance compared to its industry, KBH&#39;s current valuation is still considered undervalued. This might imply that the market has not yet fully recognized or priced in the company&#39;s potential growth prospects or earnings potential. The company is also trading currently at a discount compared to the industry&#39;s big shots like <strong>PulteGroup, Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/phm#NYSE">PHM</a>).</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6c/78792.jpg?v=689735686" /></p>
<p>Image Source: Zacks Investment Research</p>
<h2>How to Play KB Home Stock?</h2>
<p>Investors may want to hold KB Home stock due to its resilience in a challenging housing market, driven by strategic pricing and effective inventory management. Despite industry headwinds like expensive mortgages and slowing demand, KB Home has maintained strong financial performance through a focus on affordability and margin optimization. The company&#39;s BTO model has contributed to positive inventory dynamics, supporting confidence in their margin guidance for the second half of 2024.</p>
<p>While the recent Federal Reserve rate cut to 4.75%-5% may provide some market relief, its full impact on homebuilding remains uncertain, as mortgage rates may have already factored in the anticipated cut. Additionally, rising land costs, competition from the resale market, and supply chain disruptions pose challenges to the company&#39;s growth potential.</p>
<p>Though KB Home&#39;s stock has shown strength with a solid 50-day moving average and discounted valuation, a lack of upward estimate revisions in the past two months signals limited near-term upside. Investors might consider holding the stock while waiting for more favorable market conditions and further clarity on KB Home&#39;s long-term performance.</p>
<p>KB Home&#39;s operational resilience and strategic focus in a difficult environment make it a stock worth holding, although potential investors may opt for caution until clearer signals of stability emerge in both the company&#39;s performance and broader market trends.</p>
<p><a href="https://www.zacks.com/stock/news/2339964/should-you-buy-sell-or-hold-kb-home-before-q3-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2339964">To read this article on Zacks.com click here.</a></p>


Mid Cap

Guidance

Technicals

Federal Reserve

TMHC

Should You Buy, Sell, or Hold KB Home Before Q3 Earnings?

<p><a href="https://www.benzinga.com/personal-finance/24/03/37464513/older-and-wiser-now-means-being-richer-baby-boomers-own-72-of-nations-wealth-but-gen-x-and-the-y">Baby Boomers</a> between ages 60 and 78 control a massive $76 trillion in wealth. This makes them the wealthiest retiring generation in history but they aren't parting with their money as quickly as many predicted.&nbsp;</p>
<p>Economists are wondering why these retirees are holding onto their fortunes instead of spending them like earlier generations did.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"><strong> </strong><strong>How do you compare</strong></a>?</strong></li>
<li><strong>Miami is expected to take New York's place as the U.S. Financial Capital.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"><strong> </strong><strong>Here's how you can invest in the city before that happens</strong></a>.</strong></li>
<li><strong>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"><strong> </strong><strong>How does it compare to the average?</strong></a></strong></li>
</ul>
<p>A recent episode of The Economist podcast, "The Intelligence," explores this unexpected trend. Senior economics writer Colin Williams notes that the big mystery isn't why boomers are being thrifty but spending so little overall. This shift impacts everything from the housing market to how younger generations think about their financial future.</p>
<p>So, what's behind this conservative approach? A few factors seem to be at play.</p>
<p>First, COVID has left a lasting mark. Williams points out that many boomers adopted what he calls "hermit-like habits" during the pandemic and these tendencies have stuck around even after restrictions were lifted. It's almost as if they're building wealth by accident without trying to.</p>
<p><strong><em>See Also:</em></strong><em> <a href="https://www.benzinga.com/money/irs-finalizes-10-year-rule-adv"><strong><em>IRS Finalizes 10-Year Rule For Retirement Withdrawals, Making Things &#8216;Even More Insanely Complicated&#8217;</em></strong></a></em></p>
<p>Second, boomers are living longer, which raises financial concerns. A report from Corebridge Financial found that while 54% of Americans expect to live to 100, only 27% believe their savings will last that long. Boomers are eyeing a long retirement and <a href="https://www.benzinga.com/personal-finance/24/07/39780937/survey-reveals-67-of-55-year-olds-are-severely-underprepared-and-terrified-they-will-outlive-the">don't want to outlive their money</a>.</p>
<p>Then, there's the question of legacy. Many boomers feel a sense of duty to leave something behind for their children and grandchildren. "There's a lot of competing demands for their money," says Williams. He adds that boomers are "pretty stingy" with their wealth, which will not change anytime soon.</p>
<p><strong>Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"><strong>These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</strong></a></strong></p>
<p>The economic ripples from this trend are wide-ranging, <a href="https://www.benzinga.com/markets/24/09/40904058/investment-opportunities-are-popping-up-in-new-markets-as-baby-boomers-look-beyond-florida-for-retir">especially in the housing market.</a> Boomers stay put and this "aging in place" contributes to the housing shortage. A Redfin study shows the U.S. is short by four to seven million homes and three-quarters of homeowners over 60 plan to stay in their homes. This only adds pressure for younger buyers.</p>
<p>For those in Gen Z or millennials lucky enough to buy a home, it's not exactly what their parents had. Boomers own 28% of large homes with three or more bedrooms, while only 0.3% of Gen Z families can say the same.</p>
<p><strong><em>See Also:</em></strong><em> </em><strong><em>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"><strong><em> </em></strong><strong><em>The percentage may shock you</em></strong></a>.</em></strong></p>
<p>And what about the much-hyped Great Wealth Transfer? Cerulli Associates estimates that $53 trillion will pass down from boomers in the next decade. However, much of that wealth is concentrated in high-net-worth households. Plus, longer life spans and rising long-term care costs could eat into those inheritances, leaving less than younger generations hoped.</p>
<p>In the meantime, millennials and Gen Z are left to rethink their financial strategies, facing a future in which they may not receive the <a href="https://www.benzinga.com/general/24/03/37514748/boomers-are-expected-to-pass-90-trillion-in-assets-onto-millennials-leaving-them-to-become-the-riche">windfall they once anticipated.</a></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>Don&#8217;t miss the real AI boom &#8211;<a href="https://www.benzinga.com/money/fundrise-innovation-fund"><strong> here&#8217;s how to use just $10 to invest in high growth private tech companies.</strong></a></strong></li>
<li><strong><a href="https://www.benzinga.com/money/charlie-munger-100k"><strong>Charlie Munger said if you want to be rich, &#8220;find a way to get your hands on $100,000&#8221; — here&#8217;s what he means.</strong></a></strong></li>
</ul>


Personal Finance

Baby Boomers Are The 'Richest Generation Ever' But Being 'Pretty Stingy' With Their Money – And Younger Generations Are Feeling The Squeeze

UXIN

Uxin shares are trading higher after the company reported a year-over-year increase in Q1 sales results.

<p>Morgan Stanley  analyst Patrick Wood   maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Equal-Weight and maintains $45 price target.</p>


TNDM

Morgan Stanley Maintains Equal-Weight on Tandem Diabetes Care, Maintains $45 Price Target

<p>Morgan Stanley  analyst Ryan Kenny   maintains Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) with a Underweight and raises the price target from $61 to $67.</p>


Morgan Stanley Maintains Underweight on Moelis, Raises Price Target to $67

<p><strong>Lars Fruergaard Jørgensen</strong>, President and CEO of <strong>Novo Nordisk A/S</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), is set to face tough questions from the U.S. lawmakers regarding the steep prices of the company&#8217;s diabetes and weight-loss drugs, including <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39736330/bernie-sanders-targets-high-prices-of-ozempic-and-wegovy-in-us" rel="noreferrer noopener">Ozempic and Wegovy</a>.</p>
<p>The United States Senate Committee on Health, Education, Labor, and Pensions (HELP) <a target="_blank" href="https://www.help.senate.gov/hearings/why-is-novo-nordisk-charging-americans-with-diabetes-and-obesity-outrageously-high-prices-for-ozempic-and-wegovy" rel="noreferrer noopener">hearing</a> is scheduled for Tuesday, September 24th.</p>
<p>Leading the charge is Senator <strong>Bernie Sanders</strong>, chair of the Senate committee, who has been outspoken about the high cost of these medicines.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40550961/novo-nordisk-does-not-operate-as-drug-cartel-ceo-defends-us-pricing-of-ozempic-against-criticism-" rel="noreferrer noopener">Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices</a>.</strong></p>
<p>The President of the United States,&nbsp;<strong>Joe Biden,&nbsp;</strong>and&nbsp;<strong>Sen. Bernie Sanders</strong>,<em>&nbsp;</em>the Senate Chairman of the Health, Education, Labor, and Pensions Committee, have long been vocal about the exorbitant prices the pharmaceutical industry charges for prescription <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39600377/joe-biden-suggests-novo-nordisk-eli-lilly-to-lower-prices-for-its-popular-obesity-drugs" rel="noreferrer noopener">drugs in the U.S</a>.</p>
<p>Bernie Sanders <a target="_blank" href="https://www.sanders.senate.gov/in-the-news/novo-nordisk-is-ripping-off-the-american-people-bernie-sanders-says-of-ozempic-and-wegovy-costs/" rel="noreferrer noopener">said</a> the first question he would ask Novo Nordisk&#8217;s CEO at a Senate committee hearing is why the drugmaker charges up to 10 or 15 times more for&nbsp;Ozempic and Wegovy in the U.S. than other countries.</p>
<p>&#8220;This is absurd,&#8221; Sanders said in an interview late Tuesday. &#8220;It is clear that Novo Nordisk is ripping off the American people.&#8221;</p>
<p>Novo Nordisk is expected to defend the current prices, pointing to how most patients are covered by insurance and blaming pharmacy benefit managers for inflating drug prices through rebates.</p>
<p>Jørgensen is likely to highlight the extensive development costs of these drugs, which the company says exceeded $10 billion over three decades.&nbsp;&nbsp;</p>
<p>Novo Nordisk has invested over $30 billion in expanding its manufacturing capacity since early last year.</p>
<p>However, a Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-09-23/ozempic-wegovy-sales-will-cover-68-billion-in-r-d-for-novo-nordisk" rel="noreferrer noopener">analysis</a> shows that Ozempic and Wegovy&#8217;s enormous sales, which are set to surpass $65 billion by the end of this year, undermine the company&#8217;s justification for the high prices.</p>
<p>After accounting for inflation, that figure would surpass the $68 billion Novo had invested in all research and development since the mid-1990s when the company began focusing on this class of drugs.</p>
<p>According to some analysts,&nbsp;Novo Nordisk&#8217;s blockbuster diabetes drug&nbsp;Ozempic&nbsp;and several other well-known medications might be included in Medicare&#8217;s negotiated <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">prescription drug prices</a>.</p>
<p><strong>Price Action:</strong> NVO stock is down 3.10% at $123.56 at the last check Monday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/09/40985825/tesla-and-chinese-ev-startups-outpace-toyota-volkswagen-in-critical-software-race-report" target="_blank" rel="noreferrer noopener">Tesla And Chinese EV Startups Outpace Toyota, Volkswagen In Critical Software Race: Report</a>.</strong></li>
</ul>
<p><em>Photo via Shutterstock</em></p>


Biotech

Health Care

Legal

Movers

Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday

Macro Economic Events

Politics

Economics

Boeing's DC Office Cuts Political Donations, Lobbying

Treasure Global shares are trading higher after the company announced it entered into a partnership agreement with Credilab.

<p><strong>DA Davidson</strong> analyst Gil Luria downgraded the rating on <strong>Microsoft Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) to Neutral from Buy while maintaining a <a target="_blank" href="https://www.benzinga.com/quote/MSFT/analyst-ratings" rel="noreferrer noopener">price target of $475</a>.</p>
<p>Luria noted competition has essentially caught up with Microsoft on the AI front, which reduces the justification for the current premium valuation.</p>
<p>The analyst now ranked Microsoft fourth within the Magnificient Six. The stock increased 92% since his January 2023 initiation, compared to 49% for the S&amp;P500.</p>
<p>Luria noted that Microsoft has accelerated growth and extended margins over the last few quarters as the first to embrace and commercialize generative AI. Through an early investment in OpenAI and the ability to quickly deploy capabilities within Azure and GitHub, it took a significant lead over <strong>Amazon.Com Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Web Service and <strong>Alphabet Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google Cloud, which translated to superior results over the prior 4-6 quarters.</p>
<p><figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23123947/newplot-19.png" alt="" class="wp-image-561547" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23123947/newplot-19.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23123947/newplot-19-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure></p>
<p>The analyst noted that Microsoft&#8217;s lead is now diminished in both the cloud and code generation businesses, making it difficult for Microsoft to continue to outperform.</p>
<p>Luria said AWS is already adding nearly as much cloud business as Azure after a few quarters of Microsoft adding more business. Google Cloud Platform&#8217;s expansion has also seen its business accelerate to comparable growth rates as Azure prior quarter.</p>
<p>The analyst&#8217;s new proprietary hyperscaler semiconductor analysis indicates AWS and GCP are far ahead in deploying their silicon into their data centers, giving them a significant advantage over Azure in the future.</p>
<p>While Microsoft has discussed its Maia chips, it is years behind Amazon and Google and seems to be using them only to run Azure OpenAI Services workloads, he flagged. Luria noted this means Microsoft has been escalating an arms race it may not be able to prevail. He said this makes Microsoft beholden to <strong>Nvidia Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), which means it will continue to shift wealth from its shareholders to Nvidia shareholders.</p>
<p>After significant margin expansion last year, Microsoft is now guiding for a decline in operating margins to pay for the data center capex, increasing from 12% to 21% of revenue, Luria emphasized. This is a higher rate of increase than Amazon and Google due to Microsoft&#8217;s greater reliance on Nvidia.</p>
<p>The analyst said that Microsoft overinvests at these rates yearly, diminishing margins by at least 100 bps cumulatively. To offset the margin drag, Microsoft would need to lay off ~10,000 employees for every year of over-investment.</p>
<p>While Nvidia and others have pointed to a strong ROI for hyperscalers such as Azure, Luria flagged that these returns may only last for a while.</p>
<p>The analyst noted Azure&#8217;s growth may be boosted by self-funded revenue, such as from OpenAI.</p>
<p>Luria noted Microsoft has also lost much of the lead for GitHub Copilot. Not only have Amazon and Gitlab mostly caught up to GitHub Copilot&#8217;s capabilities, he said Cursor has become the new standard.</p>
<p>Luria projected fiscal first-quarter 2025 revenue of $64.2 billion and EPS of $2.96.</p>
<p><strong>Price Action:</strong> MSFT stock is down 0.50% at $433.10 at last check Monday.</p>
<p><em>Photo via Shutterstock</em></p>


Analyst Color

Downgrades

Tech

AMZN

GOOG

GOOGL

MSFT

NVDA

Microsoft's AI Lead Shrinks: Analyst Downgrades Stock As Amazon And Google Close The Gap

EWU: Why U.K. Stocks Are Poised For A Comeback

Warning: DNNGY is at high risk of performing badly

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><a href="https://investorplace.com/stock-types/growth-stocks/">Growth stocks</a> have been on a wild ride for the past few years. The pandemic sent many soaring to unbelievable heights. Then, rising rates and recession fears brought them crashing back to earth. But I believe the growth stock story is far from over. In fact, with the Fed now signaling rate cuts are on the horizon, I think growth stocks are poised for an epic comeback.</p>



<p>Sure, many growth names are still quite risky. Chasing the latest meme stock or unproven biotech is a good way to lose your shirt. However, for investors with a long-term mindset, now is the perfect time to start building positions in high-quality growth stocks.</p>



<p>As rates come down and the economy stabilizes, these businesses could deliver explosive returns. I wouldn&rsquo;t be surprised to see some of the best growth stocks 5X or more in value over the next five years. Of course, you have to be selective and manage your risk. But if you&rsquo;re aiming for outsized gains, having some exposure to growth is a must. Here are seven growth stocks that have the potential to be mega-winners.</p>



<h2>Cadeler (CDLR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/money-bag-growth-stocks-1600-300x169.jpg" alt="Graphic of yellow money bag next to green arrow and coins floating in air, symbolizing growth stocks"><div>Source: shutterstock.com/Monster Ztudio</div></div><p><strong>Cadeler</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/cdlr-stock-quote/"><strong>CDLR</strong></a>) installs and maintains offshore wind farms with its fleet of specialized vessels. These massive turbines out at sea generate more consistent power than their land-based counterparts without noise complaints. Cadeler seems perfectly positioned to ride this wave of clean energy expansion.</p>



<p>Analysts project the company&rsquo;s revenue to <a href="http://seekingalpha.com/symbol/CDLR/earnings/estimates" target="_blank">surge from $255 million </a>in 2024 to over $1 billion by 2027. Earnings per share is expected to skyrocket from just 20 cents to $1.86 in that same period. With numbers like these, I wouldn&rsquo;t be surprised to see Cadeler&rsquo;s stock deliver 5x returns or more.</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/07/chart-67.png"><img width="1200" height="628" src="https://investorplace.com/wp-content/uploads/2024/07/chart-67.png" alt="Growth stocks: Cadeler Revenue EBIT Estimates"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><p>The company keeps racking up new contracts, too. They recently inked a deal with <strong>Orsted</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/dnngy-stock-quote/"><strong>DNNGY</strong></a>) for a long-term vessel lease starting in 2027.</p>



<p>Of course, I have to temper my enthusiasm with a dose of realism. Cadeler operates in a capital-intensive industry with plenty of risks. Weather delays, project cancellations, or new competitors could throw a wrench in their plans. But from where I&rsquo;m sitting, the potential rewards far outweigh the risks for this offshore wind pure-play.</p>



<h2>Megaport (MGPPF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/growthstocks_1600_02-300x169.jpg" alt="Hand of woman watering small plant in pot shaped like growing graph representing growth stocks. Sleeper Growth Stocks"><div>Source: Khakimullin Aleksandr / Shutterstock</div></div><p><strong>Megaport</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/mgppf-stock-quote/"><strong>MGPPF</strong></a>) operates a global software-defined network platform that enables businesses to connect their networks to cloud services and data centers. Thanks to the AI revolution, the data center industry is booming and this trend will only accelerate in the coming years. Megaport is perfectly positioned to ride this wave of growth.</p>



<p>Megaport reported impressive numbers. <a href="https://markets.businessinsider.com/news/stocks/australian-stocks-megaport-shares-fall-as-upgraded-forecast-disappoints-1033299336" target="_blank">Revenue increased 30% </a>year-over-year to 49.5 million AUD, while EBITDA nearly doubled to 14 million AUD. The company also upgraded its full-year EBITDA guidance.</p>



<p>Despite these strong results, Megaport&rsquo;s stock price took a hit recently. Regardless, this company is profitable and growing rapidly, with plenty of runway ahead as the data center and AI industries continue to expand.</p>



<p>Sure, there are risks to consider. Megaport&rsquo;s success hinges on sustained growth in AI and data center demand. But given the massive investments pouring into these sectors, I&rsquo;m optimistic about the company&rsquo;s prospects.</p>



<h2>Ouster (OUST)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/growth-confidence-300x169.png" alt="An image of a man relaxing, sleeping on a stock growth chart; growth stocks"><div>Source: eamesBot / Shutterstock</div></div><p><strong>Ouster</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/oust-stock-quote/"><strong>OUST</strong></a>) makes high-resolution digital lidar sensors for autonomous vehicles, robotics and smart infrastructure. This company is poised to ride the massive robotics and automation adoption wave in the coming years. The lidar industry could surge as companies across sectors embrace these technologies, and Ouster seems uniquely positioned to capitalize. Their recent financial performance has been stellar compared to lidar peers. It is still unprofitable, but analysts project Ouster could reach profitability by 2027 with significant growth after that. If analyst estimates pan out, you&rsquo;re looking at just 3x 2027 earnings at current prices.</p>



<p>Of course, it&rsquo;s speculative at this stage. But I see multibagger potential here if robotics continues its exponential growth and EVs come back with increased lidar usage. The stock has surged lately on strong Q1 results, with <a href="https://finance.yahoo.com/news/ouster-announces-record-revenue-margin-201500186.html" target="_blank">revenue up 51% year-over-year to $26 million</a>. Several analysts have boosted price targets, including Craig-Hallum to $13 and Rosenblatt to $17.</p>



<h2>ClearPoint Neuro (CLPT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/05/brain-400x225-1-300x169.png" alt="A concept image of a glowing blue brain to depict AI"><div>Source: Andrus Ciprian / Shutterstock.com</div></div><p><strong>ClearPoint Neuro</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/clpt-stock-quote/"><strong>CLPT</strong></a>) makes platforms for performing minimally invasive surgical procedures in the brain. CLPT stock has surged about 40% in the past two weeks and could climb even higher if the company maintains its growth trajectory and continues making medical breakthroughs. </p>



<p>While I typically steer clear of small biotech firms, I think it is worth considering CLPT. I&rsquo;m personally quite bullish on gene-editing companies. These cutting-edge businesses have the potential to cure a wide array of diseases and boast extensive pipelines. This optimism extends to ClearPoint Neuro as well.</p>



<p>In Q1, <a href="https://www.investing.com/news/stock-market-news/earnings-call-clearpoint-neuro-sees-robust-q1-growth-with-diverse-revenue-streams-93CH-3430774" target="_blank">revenue rose 41% year-over-year</a> to $7.6 million. That&rsquo;s not too bad, considering this top-line number beat estimates by 9.23%. It still trades at quite a steep sales premium, but I see multiple catalysts on the horizon that could keep sales growing fast.</p>



<p>Cash is also one of the most important metrics for an unprofitable biotech company. This company&rsquo;s cash holdings are around $35 million, which is satisfactory considering its $4.15 million in net losses in Q1.</p>



<h2>Block (SQ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/sq-block-1600-300x169.png" alt="Square, Inc. changes name to Block (SQ). Smartphone with Square logo on screen in hand on background of Block logo."><div>Source: Sergei Elagin / Shutterstock.com</div></div><p><strong>Block</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/sq-stock-quote/"><strong>SQ</strong></a>) is much more than just a <strong>PayPal</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/pypl-stock-quote/"><strong>PYPL</strong></a>) alternative as it has been in the past. It has delivered impressive financial results recently, with <a href="https://www.cnbc.com/2024/05/02/block-sq-earnings-q1-2024.html" target="_blank">Q1 2024 revenue of $5.96 billion</a> beating estimates and adjusted EPS of 85 cents, surpassing expectations. Block raised its full-year 2024 guidance, now expecting gross profit of at least $8.78 billion (17% growth) and adjusted operating income of at least $1.3 billion. If we look at fundamentals, this stock should&rsquo;ve recovered to around $100 many months ago, but the broader fintech industry has not been cooperating.</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/07/chart-68.png"><img width="1200" height="628" src="https://investorplace.com/wp-content/uploads/2024/07/chart-68.png" alt="Block EPS revenue estimates"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><p>That said, analysts are now projecting EPS to <a href="https://seekingalpha.com/symbol/SQ/earnings/estimates" target="_blank">increase from $3.4 in 2024 to $15 by 2033</a> &mdash; and it is expected to double from 2024 by 2028. Block&rsquo;s stock has been trading sideways at a discounted level due to the depressed fintech sector; rising EPS should lead to an eventual breakout.</p>



<p>Moreover, impending interest rate cuts could also catalyze a major rally for Block. Block could deliver 5x returns in five years if the market fully appreciates its profitable growth. Management would need to surpass those optimistic EPS expectations I mentioned above. Can they do it? That&rsquo;s for you to bet on.</p>



<h2>Fastly (FSLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/07/fsly-stock-1-300x169.jpg" alt="A magnifying glass zooms in on the Fastly (FSLY) website."><div>Source: Pavel Kapysh / Shutterstock.com</div></div><p><strong>Fastly</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/fsly-stock-quote/"><strong>FSLY</strong></a>) operates a content delivery network that enables faster and more reliable delivery of digital content. Fastly is an exciting bet on the future of cloud computing, edge computing and streaming over the next five years. Yes, the stock has plummeted nearly 58% in the past year amid concerns over slowing growth and mounting losses. However, shares have stabilized recently, and Fastly could deliver outsized returns.</p>



<p>Analysts seem cautiously optimistic, with an <a href="https://www.tipranks.com/stocks/fsly/forecast" target="_blank">average price target of $9.8</a>, implying a 29% upside from current levels. The company also reported solid Q1 results, with <a href="https://www.investing.com/news/company-news/fastly-cfo-sells-shares-worth-over-87000-93CH-3508018" target="_blank">revenue up 14% year-over-year to $133.5 million</a>, beating estimates.</p>



<p>Looking ahead, Fastly is expected to turn profitable in 2025. You are currently paying <a href="https://seekingalpha.com/symbol/FSLY/earnings/estimates" target="_blank">just four times 2030 earnings</a>, though I will warn again that these estimates are very speculative.</p>



<p>Regardless, the risk-reward looks favorable for people willing to ride out the volatility. Cloud and edge computing are clear megatrends that should provide strong long-term tailwinds for Fastly&rsquo;s business.</p>



<h2>freee K.K. (FREKF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/brokerageaccount1600-300x169.jpg" alt="A pile of $100 bills on a black background with a smartphone displaying a stock chart on top."><div>Source: etonastenka / Shutterstock.com</div></div><p><strong>freee K.K.</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/frekf-stock-quote/"><strong>FREKF</strong></a>) specializes in delivering cloud-based accounting and HR software solutions to small and medium-sized businesses in Japan. This company is poised for hypergrowth as more Japanese companies rush to digitize their back-office operations. In fact, freee&rsquo;s <a href="https://www.google.com/finance/quote/FREKF:OTCMKTS" target="_blank">revenue surged 31% year-over-year to 6.65 billion Yen</a> in Q1 2024.</p>



<p>Despite this impressive performance, freee&rsquo;s stock is still down nearly 78% from its all-time high. A weakening Japanese Yen has been a headwind for the company. However, I think the worst may be over for the stock. As global interest rates stabilize and the Yen potentially recovers, investor sentiment toward Japanese equities could improve.</p>



<p>Japan is finally ending its negative interest rate policy, and I expect the macroeconomic environment to become more favorable for growth stocks like freee.</p>



<p><em>On the date of publication, Omor Ibne Ehsan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a></em>.</p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Omor Ibne Ehsan is a writer at InvestorPlace. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks. You can follow him on <a href="https://www.linkedin.com/in/omor-ibne-ehsan-56068022b/">LinkedIn</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/07/7-growth-stocks-that-could-5x-in-5-years/">7 Growth Stocks That Could 5X in 5 Years</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Growth Stocks That Could 5X in 5 Years

Ørsted: More Of A Speculative Buy Now

Ørsted A/S GAAP EPS of -DKK 4.10, revenue of DKK 15.02B; reaffirms FY24 outlook

Ørsted flags delay in U.S. offshore wind, scraps European green fuels project

Orsted A/S. (DNNGY) Q2 2024 Earnings Call Transcript

ØRsted's Halt On Hydrogen Plant Highlights Synthetic Fuel Challenge

In a report released on August 30, Ingo Becker from Kepler Capital maintained a Hold rating on Orsted (DOGEF – Research Report), with a price targe...

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Orsted

Orsted (DNNGY) Forecast

Orsted (OTC:DNNGY) Stock, Quote.Headers.trade-ideas